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Abstract
Introduction: The first World Health Organization (WHO) global health sector strategy on hepatitis B and C viruses (HBV
and HCV) has called for the elimination of viral hepatitis as a major public health threat by 2030. This study assesses policies
and programmes in support of elimination efforts as reported by patient groups in Europe.
Methods: In 2016 and 2017, hepatitis patient groups in 25 European countries participated in a cross-sectional survey about
their countries’ policy responses to HBV and HCV. The English-language survey addressed overall national response; public
awareness/engagement; disease monitoring; prevention; testing/diagnosis; clinical assessment; and treatment. We performed a
descriptive analysis of data and compared 2016 and 2017 findings.
Results: In 2017, 72% and 52% of the 25 European study countries were reported to not have national HBV and HCV strate-
gies respectively. The number of respondents indicating that their governments collaborated with civil society on viral hepatitis
control increased from 13 in 2016 to 18 in 2017. In both 2016 and 2017, patient groups reported that 9 countries (36%) have
disease registers for HBV and 11 (44%) have disease registers for HCV. The number of countries reported to have needle and
syringe exchange programmes available in all parts of the country dropped from 10 (40%) in 2016 to 8 in 2017 (32%). In both
2016 and 2017, patient groups in 5 countries (20%) reported that HCV treatment is available in non-hospital settings. From
2016 to 2017, the reported number of countries with no restrictions on access to direct-acting antivirals for HCV increased
from 3 (12%) to 7 (28%), and 5 fewer countries were reported to refuse treatment to people who are currently injecting drugs.
Conclusions: The patient-led Hep-CORE study offers a unique perspective on the readiness of study countries to undertake
comprehensive viral hepatitis elimination efforts. Viral hepatitis monitoring should be expanded to address policy issues more
comprehensively and to incorporate civil society perspectives, as is the case with global HIV monitoring. Policy components
should also be explicitly added to the WHO framework for monitoring country-level progress against viral hepatitis.
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1 | INTRODUCTION
Viral hepatitis is a major public health problem, with more
deaths annually attributable to this group of diseases than to
HIV, malaria or tuberculosis [1]. Hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections account for 47% and 48%
of viral hepatitis mortality respectively [2]. Both HBV and
HCV infections can lead to cirrhosis and liver cancer, and
most HBV- and HCV-related deaths occur as a direct result
of one of these two diseases [1]. HBV and HCV together are
estimated to account for almost 80% of deaths from liver can-
cer [3,4], which was the third most common cause of cancer
mortality in 2013 [5].
In the WHO European Region an estimated 18.5 million
people are chronically infected with HBV, and an estimated
15 million people are chronically infected with HCV [6,7]. The
annual number of deaths from viral hepatitis-related causes in
the Region is thought to exceed 170,000 [8]. With HBV vacci-
nation now widespread in younger age groups, HBV tends to
be seen more in older Europeans and in migrants from
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countries with high HBV prevalence [8]. Practices associated
with unsafe injecting drug use are a major contributor to the
HCV epidemic in the European Region. There are high levels
of HCV transmission among HIV-positive men who have sex
with men, and healthcare-related transmission of HCV contin-
ues to occur in some countries [9,10]. The recent introduction
of highly effective direct-acting antiviral (DAA) drugs has made
HCV much easier and safer to cure, but concern has been
raised about whether health systems in Europe and globally
will be able to overcome the numerous barriers to scaling up
DAA treatment [10-12].
In 2014, in response to increasing recognition of the
large disease burden imposed by viral hepatitis, the World
Health Assembly approved a resolution calling on WHO
Member States to enact various viral hepatitis control mea-
sures. The same resolution charged WHO with examining
“the feasibility of and strategies needed for the elimination
of hepatitis B and hepatitis C with a view to potentially set-
ting global targets” [13]. In this policy context, the European
Liver Patients’ Association (ELPA) published 43 key recom-
mendations for European governments [14]. ELPA subse-
quently commissioned the Hep-CORE (“Hepatitis –
Community, Opinion, Recommendations, Experts”) study to
assess the extent to which these recommendations are
being followed on a national level in European countries. As
the Hep-CORE study was being planned, other major policy
developments occurred. In 2015, United Nations Member
States included a commitment to combat viral hepatitis in
the Sustainable Development Goals [15] and in 2016, WHO
launched its first global health sector strategy on viral hep-
atitis [2]. The strategy sets forth the ambitious targets of
achieving a 90% reduction in new cases of chronic HBV
and HCV and a 65% reduction in HBV and HCV deaths, all
by 2030 [2].
To reach the targets and achieve WHO’s overarching goal
of eliminating viral hepatitis as a major public health threat by
2030, governments around the world must first consider
whether they have the necessary policies and programmes in
place. Scant information is available regarding the current pol-
icy landscape. The 2013 Global Policy Report on the Prevention
and Control of Viral Hepatitis in WHO Member States presents
findings from a policy survey completed by representatives of
126 national governments [16]. A follow-up survey of civil
society organizations found that numerous respondents
questioned the accuracy of the information reported by their
governments [17].
Policy monitoring of national responses to major health
issues has been approached in a variety of ways [18,19]. A
key example is the global HIV policy monitoring process coor-
dinated by the Joint United Nations Programme on HIV/AIDS
(UNAIDS) for more than a decade. Governments are asked to
prepare periodic reports on their countries’ progress in com-
bating HIV, with some of the information gathered using a
survey known as the National Commitments and Policy Instru-
ment (NCPI) [20]. Significantly, one part of the NCPI is com-
pleted by governments and the other by in-country civil
society stakeholders.
With no ongoing government or multi-stakeholder policy
monitoring process for viral hepatitis in place at the global or
regional level, ELPA sought to fill a gap by implementing the
Hep-CORE study in the countries where it had member
organizations. These patient groups were responsible for
reporting information to the study team. ELPA’s goal was two-
fold: (1) to help liver patient groups identify key policy short-
comings in study countries; and (2) to engage liver patient
groups in a regional policy monitoring initiative that will help
hold countries accountable to their pledges to work towards
viral hepatitis elimination. The following article reports findings
from the 2016 and 2017 Hep-CORE surveys.
2 | METHODS
A research team based at the University of Barcelona and the
University of Copenhagen implemented the Hep-CORE study
in consultation with a multidisciplinary study group of viral
hepatitis experts and carried out two rounds of data collec-
tion: one from July to October 2016 and another from August
to November 2017.
The original study instrument, a 39-item English-language
online survey (Additional File 1), reflected ELPA’s recommen-
dations to European governments [14]. We developed and
revised the survey in accordance with multiple rounds of input
from study group members. The 2016 survey questions
addressed issues relating to all seven categories of recom-
mendations: overall national response, public awareness and
engagement, monitoring and data collection, prevention, test-
ing and diagnosis, clinical assessment, and treatment. The
study instrument was piloted in June 2016. Four prospective
study participants completed the survey and provided feed-
back, which guided final revisions. The Hep-CORE 2017 study
instrument comprised 11 questions derived from the 2016
survey (Additional File 2). We piloted it in August 2017 with
five study group members. The pilot responses and additional
feedback guided survey modifications.
As in 2016, the main survey questions in 2017 were
closed-ended, as were most sub-questions. For both rounds of
data collection, we asked study participants to complete the
survey using Research Electronic Data Capture (REDCap), a
web-based data collection tool that enables responses to be
saved and edited over the course of multiple sessions [21].
The survey instructions asked respondents to conduct
research as needed to answer survey questions accurately,
and recommended contacting sources such as government
officials and viral hepatitis experts. Respondents were able to
pause work on their surveys and log back into them to change
or add information using unique access codes.
The study cohort was recruited through a purposive sam-
pling process. We emailed an invitation to participate in the
survey to one liver patient group in each of the 24 European
countries where ELPA had members at the time of 2016
study recruitment. In countries with more than one patient
group, we selected the most representative group that was
involved in viral hepatitis advocacy. We also emailed the invita-
tion to a liver patient group in Denmark, since the patient
group was just about to join ELPA, and did so in 2017. The
same 25 patient groups that accepted the invitation and con-
tributed data in 2016 were invited to respond to the 2017
survey. Many of the same individuals completed the survey in
both years, although personnel changes in some patient
groups meant that in some cases different individuals repre-
sented those groups in 2017.
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Following the close of each round of data collection, we
reviewed data and queried study participants via email
about incomplete, inconsistent or unclear information. We
compiled and descriptively analysed final data using Micro-
soft Excel. We reported 2016 findings in The 2016 Hep-
CORE Report, published by ELPA in early 2017 [22]. The
analysis presented in this paper directly compares 2017
findings to findings from parallel 2016 survey questions.
Additional File 3 provides country responses to the 2016
and 2017 surveys in comparative tables.
3 | RESULTS
In both 2016 and 2017, the 25 European liver patient groups
that received study invitations all submitted surveys, for a
100% response rate. Box 1 identifies the countries repre-
sented by these groups.
3.1 | National coordination
In 2017, patient groups in seven countries (28%) reported
that their countries have written national strategies for HBV,
and patient groups in 12 countries (48%) reported the same
for HCV (Table 1). These findings were similar to 2016 find-
ings, although the survey questions were formulated slightly
differently in 2016 and 2017 (Additional Files 1 and 2). The
number of patient groups reporting government collaboration
with in-country civil society groups to carry out viral hepati-
tis prevention and control programmes increased from 13
(52%) in 2016 to 18 (72%) in 2017. In both 2016 and
2017, patient groups reported that nine countries (36%)
have disease registers for HBV and 11 (44%) have disease
registers for HCV.
3.2 | Prevention
While patient groups in most study countries reported opioid
substitution therapy (OST) to be available in all parts of the
country in both 2016 and 2017, far fewer reported needle
and syringe programmes (NSPs) to be available in all parts of
the country – 10 (40%) in 2016 and 8 (32%) in 2017
(Table 1). Drug consumption rooms were reported to be avail-
able in either all or some parts of the country in four coun-
tries (16%) in 2016 and six countries (24%) in 2017.
3.3 | Testing
HBV/HCV risk assessment was reported to be included in
routine medical check-ups in six countries (24%) in 2017, and
liver enzyme testing in 14 countries (56%) (Table 1).
Patient groups were asked to indicate whether free and
anonymous HBV and HCV testing services targeting the gen-
eral population and high-risk populations are available in their
countries (Figure 1). From 2016 to 2017, large increases
occurred in the number of countries reported to have anony-
mous HBV and HCV testing for the general population, with
anonymous HBV testing up from six to twelve countries and
anonymous HCV testing up from six to eleven countries.
There also were large increases for free HBV and HCV test-
ing for the general population, and for anonymous HCV test-
ing for high-risk populations.
Eighteen countries (72%) reported HBV testing availability
outside of hospitals in 2017, with the same number of coun-
tries reporting HCV testing/screening availability outside of
hospitals in that year though with slight variation for HBV and
HCV (data not shown). Types of testing sites included general
practitioner clinics (HBV, 11 countries; HCV, 10 countries),
OST clinics (HBV, 9 countries; HCV, 10 countries) and NSPs
(HBV, 5 countries; HCV 7 countries). In 2016, study partici-
pants were asked about non-hospital-based HBV and HCV
testing and screening in a different way, with separate survey
questions addressing the general population and high-risk pop-
ulations. Eleven countries (44%) in 2016 were reported to
have HBV testing sites outside of hospitals for the general
population, and 16 (64%), for high-risk populations. Regarding
HCV testing, the reported numbers of countries with non-hos-
pital-based sites in 2016 were 13 for the general population
(52%) and 16 for high-risk populations (64%).
3.4 | Treatment
In 2017, patient groups in 19 countries (76%) reported that
HBV treatment is provided in prisons, up from 18 countries
(72%) in 2016 (Table 1). In both 2016 and 2017, patient
groups in five countries (20%) reported that HCV treatment
is available in non-hospital settings. These included general
practitioner clinics (three countries in both 2016 and 2017),
liver specialist clinics (one country in 2016 and two countries
in 2017), and addiction/OST clinics (three countries in 2016
and two countries in 2017) (data not shown).
Box 1.
Hep-CORE European study countries
Austria Greece Slovakia
Belgium Hungary Slovenia
Bosnia and Herzegovina Italy Spain
Bulgaria Macedonia Sweden
Croatia Netherlands Turkey
Denmark Poland Ukraine
Finland Portugal United Kingdom
France Romania
Germany Serbia
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In both 2016 and 2017, survey respondents were asked to
choose one or more answers to the question, “In practice,
what restrictions are there on access to direct-acting antivirals
for the treatment of HCV infection in your country?” (Fig-
ure 2). From 2016 to 2017 the reported number of countries
with no restrictions increased from 3 (12%) to 7 (28%). Coun-
tries with a reported fibrosis level restriction dropped from
18 (72%) to 13 (52%), and countries reported to refuse treat-
ment to people who are currently injecting drugs dropped
from 13 (52%) to 8 (32%).
Table 1. National coordination, monitoring, prevention, screening and treatment policies reported for hepatitis B and hepatitis C in
study countries (N=25)
2016 2017
Yes No
Do not
know Yes No
Do not
know
National coordination
Written national HBV strategy 8 (32%) 17 (68%) 0 7 (28%) 18 (72%) 0
Written national HCV strategy 11 (44%) 14 (56%) 0 12 (48%) 13 (52%) 0
Government collaborates with
in-country civil society groups
to plan and carry out its viral
hepatitis programmea
13 (52%) 9 (36%) 3 (12%) 18b (75%) 5b (21%) 1b (4%)
Government or government-
related institution has national
HBV disease register
9 (36%) 16 (64%) 0 9 (36%) 15 (60%) 1 (4%)
Government or government-
related institution has national
HCV disease register
11 (44%) 14 (56%) 0 11 (44%) 14 (56%) 0
Prevention
Harm reduction services
available: Needle and syringe
programmes (all parts of
country, some parts of country)
All: 10 (40%) Some:
10 (40%)
4 (16%) 1 (4%) All: 8 (32%) Some: 12 (48%) 3 (12%) 2 (8%)
Harm reduction services
available: Opioid substitution
therapy (all parts of country,
some parts of country)
All: 22 (88%) Some: 1 (4%) 0 2 (8%) All: 20 (80%) Some: 4 (16%) 0 1 (4%)
Harm reduction services
available: Drug consumption
rooms (all parts of country,
some parts of country)
All: 2 (8%) Some: 2 (8%) 17 (68%) 4 (16%) All: 1 (4%) Some: 5 (20%) 16 (64%) 3 (12%)
Screening
Risk assessment for HBV/HCV
included in routine medical
check-ups
5 (20%) 20 (80%) 0 6 (24%) 18 (72%) 1 (4%)
Liver enzyme testing included in
routine medical check-ups
17 (68%) 8 (32%) 0 14 (56%) 10 (40%) 1 (4%)
Treatment
HBV treatment provided in
prisons
18c (75%) 5c (21%) 1c (4%) 19 (76%) 5 (20%) 1 (4%)
HCV patients have option to be
treated in non-hospital settingsd
5 (20%) 20 (80%) 0 5 (20%) 20 (80%) 0
HBV, hepatitis B virus; HCV, hepatitis C virus.
aSurvey respondents were advised that the following are not considered in-country civil society groups: United Nations agencies, international
non-governmental organizations, government ministries, university programmes and military programmes.
b2017 responses to this question total 24 instead of 25 because there was one non-response.
c2016 responses to this question total 24 instead of 25 because there was one non-response.
dSettings that are not within either inpatient or outpatient hospital facilities.
Lazarus JV et al. Journal of the International AIDS Society 2018, 21(S2):e25052
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25052/full | https://doi.org/10.1002/jia2.25052
12
4 | DISCUSSION
The Hep-CORE study was conducted in 2016 and 2017
against the backdrop of rapid changes in the field of viral hep-
atitis. It found that, from the perspective of liver patient
groups, many European countries have shortcomings across
the spectrum of elements that constitute a comprehensive
policy response to viral hepatitis, including national coordina-
tion, public awareness, disease surveillance, prevention, testing
and treatment. At the time of 2017 data collection, only 28%
and 48% of the 25 European study countries were reported
to have national HBV and HCV strategies respectively.
National disease registers were reported to be lacking in
many countries as well. Some key prevention, testing and
treatment recommendations did not appear to be widely
reflected in national viral hepatitis control efforts, suggesting
that governments may be missing important opportunities to
limit disease transmission, disease progression and mortality.
Despite the availability of many simple operational interven-
tions to improve the continuum of care for people with
chronic HBV and HCV, relatively few of these people are
offered treatment [23,24]. At the same time, there are prob-
lematic gaps in disease prevention efforts [23]. The Hep-CORE
study provides a patient group perspective on policy barriers
that may be undermining progress against HBV and HCV in
the European Region, while at the same time offering a model
for how patient groups might contribute to policy monitoring
in other regions. Findings indicate that few study countries
are sufficiently attuned to the importance of addressing the
HBV and HCV prevention and treatment needs of the key
populations most affected by these diseases in Europe, such
as people who inject drugs (PWID). NSPs can contribute sub-
stantially to reducing transmission of blood-borne viruses
among PWID [25,26], yet less than one-third of study coun-
tries were reported to have NSPs available in all parts of their
countries in 2017. The presence of injecting drug use-related
restrictions on access to DAAs for the treatment of HCV in
several study countries is also a matter of concern, and other
research has similarly documented such restrictions [27].
European and global experts concur that injecting drug use
Figure 1. Reported availability of free and anonymous viral hepatitis testing services in study countries (N=25)
Figure 2. Reported restrictions on access to direct-acting antivirals for the treatment of hepatitis C in study countries (N=25)
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does not constitute a valid reason for withholding treatment
[28-30] – indeed, global HCV elimination strategies depend on
the reductions in transmission that are expected to occur
when large numbers of chronically HCV-infected people who
currently inject drugs are cured with DAAs [31].
Hep-CORE 2016 and 2017 study findings differ regarding
the number of countries reported to have components of the
recommended HBV and HCV policy infrastructure in place. We
hypothesise that some small changes from 2016 to 2017 may
be attributable to how respondents interpreted questions dif-
ferently from one year to the next, or in some cases to
changes in how questions were formulated in the study instru-
ment. It is also possible that respondents became more knowl-
edgeable and thus provided more accurate information about
some issues in the second round of reporting. We are there-
fore disinclined to interpret small changes from 2016 to 2017
as trends. The magnitude of some changes, however, is notable.
The number of respondents indicating that their governments
collaborated with civil society on viral hepatitis control
increased considerably from 2016 to 2017, as did the number
of respondents reporting the availability of free and anony-
mous HBV and HCV testing for the general population. Also,
the number of study countries reported to have no restrictions
on access to DAAs for HCV treatment increased from three to
seven, with fewer countries reported to restrict access accord-
ing to fibrosis or drug injecting status. These changes might
partially reflect efforts to encourage European governments to
align their responses to viral hepatitis with global and regional
guidance. Patient groups’ research inquiries for the 2016 sur-
vey and ELPA’s extensive dissemination of study findings may
have influenced governments as well.
Researchers have proposed that the global HIV policy moni-
toring process led by UNAIDS can serve as a useful model for
other monitoring initiatives, such as those that will be needed
to track countries’ efforts to achieve the Sustainable Develop-
ment Goals [32]. The UNAIDS reporting framework repeats
some of the same questions in surveys that are completed
separately by government and civil society representatives.
This makes it possible to examine points of disagreement.
Interestingly, an assessment of differences between govern-
ment reporting and civil society reporting in the aforemen-
tioned NCPI found that civil society stakeholders generally
characterize national HIV responses less favourably than gov-
ernments do [33]. The discrepancies are allowed to stand as
part of the evidence presented in the final country reports
[20]. This point may be instructive for the viral hepatitis field,
where civil society stakeholders have challenged some govern-
ments’ accounts of their countries’ policy and programmatic
responses to viral hepatitis [16,17]. Researchers have docu-
mented increased collaboration between governments and
civil society stakeholders on NCPI reporting over time, and
have concluded that this approach has strengthened the over-
all response to HIV [32,33].
In the field of viral hepatitis, WHO has proposed a monitoring
framework for countries to track progress towards the targets
in the WHO global strategy [34]. The 10 core indicators recom-
mended by WHO ask about disease incidence, prevalence and
mortality, as well as a number of key interventions. The empha-
sis is thus on outputs rather than on indicators of a strong policy
environment. It is not known how many countries have adopted
the WHO monitoring framework since it was published in April
2016, or when WHO will establish mechanisms for countries to
publicly report their monitoring findings. We must consider how
such monitoring should be expanded to address policy issues
more comprehensively, and how future monitoring processes
should be structured, with consideration given to the role of
civil society stakeholders such as the patient groups that partici-
pated in the Hep-CORE study. Furthermore, we are not aware
of similar data being collected in other regions of the world;
conducting such an exercise in other regions would provide the
basis for comparative analyses.
Arguably, the central limitation of this study is that patient
groups were the only participants. Patient groups, especially
those that lack established communication channels with gov-
ernment officials or viral hepatitis experts, may not always be
the most well-placed to report accurately on national policies.
However, patients have a distinctly different perspective from
other stakeholders, arising from unique motivations. This may
enable them to report on policy shortcomings that other
observers have failed to identify. In designing a study that
gathered policy information only from ELPA patient groups,
the research team was both seeking to make optimal use of
limited resources and also to emphasize the importance of
patient engagement in the viral hepatitis policy discourse. It is
hoped that government representatives in all Hep-CORE
study countries will review the information reported for their
countries (Additional File 3) and will share their perspectives
on this information with the reporting patient groups. Ulti-
mately, governments and other viral hepatitis stakeholders in
Europe and elsewhere should have the goal of establishing an
ongoing viral hepatitis policy monitoring process that incorpo-
rates the expertise of all stakeholders.
Additional study limitations should be noted. The question-
naire was exclusively in English, which may have led to the mis-
interpretation of questions, despite the study team inviting
respondents to ask for clarification on any survey questions
that they did not understand. Only one patient group, or in the
case of the United Kingdom a coalition of two groups, served
as a respondent from each country; thus, the information pro-
vided might not reflect the perspectives of other patient groups
in the study countries. Because the study focused on patient
group reporting, survey answers were not checked against
other sources of information, and it is not possible to know
whether the information reported is accurate. Some respon-
dents may have been hampered in their reporting efforts by
inadequate government communication about existing policies.
5 | CONCLUSIONS
Although planning for the Hep-CORE study commenced
before the official launch of the WHO global health sector
strategy on viral hepatitis, it anticipated many of the strategy’s
key points. As such, Hep-CORE offers unique insights into the
readiness of study countries to pursue hepatitis elimination
targets. The finding that warrants the most urgent attention is
the reported absence of written national HBV and HCV
strategies in many European countries. Other key policy barri-
ers impeding viral hepatitis elimination efforts include wide-
spread restrictions to treatment, limited availability of free
and anonymous testing, and insufficient access to testing, pre-
vention and treatment in non-hospital settings. As Hep-CORE
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is driven by patient engagement, it has the potential to foster
greater interaction and cooperation between governments
and patient groups. Future policy monitoring in the Hep-
CORE countries and elsewhere should incorporate the per-
spectives of additional stakeholder groups including govern-
ments and medical professionals in order to ensure the most
reliable reporting, while also reflecting points of disagreement
among reporting parties. Frequent rounds of policy monitoring
are needed in the light of how rapidly the public health
response to viral hepatitis is evolving in Europe and else-
where.
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